Shares of ResMed Inc. RMD slid 3.83% to $205.17 Friday, on what proved to be an all-around dismal trading session for the ...

StockNews.com downgraded shares of ResMed (NYSE:RMD – Free Report) from a buy rating to a hold rating in a research report report published on Wednesday morning. A number of other equities research ...

BofA lowered the firm’s price target on ResMed (RMD) to $280 from $290 and keeps a Buy rating on the shares. The firm updated its model for ...

NightOwl is now widely available across the United States. Individuals interested in NightOwl should speak with their healthcare provider for more information. To learn more, visit: https://www.resmed ...

We recently published a list of Jim Cramer is Discussing These 10 Stocks Ahead of Q1 Earnings Season. In this article, we are ...

The home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea ...

ResMed (NYSE:RMD) launched NightOwl™, a home sleep apnea test that enhances user convenience with a small fingertip sensor and cloud data evaluation. Despite the broader market reacting negatively to ...

We came across a bullish thesis on ResMed Inc. (RMD) on Substack by LongTermValue Research. In this article, we will summarize the bulls’ thesis on RMD. ResMed Inc. (RMD)’s share was trading at $223 ...

Leading health technology, Resmed, has announced its home sleep apnea test, NightOwl, is now available across the United ...

Which is the better option for ASX investors, Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) or ResMed Inc. (ASX: RMD) ...

People have complained about Apple Vision Pro's weight, so ResMed built the Kontor Head Strap that helps by adding ...

ResMed Inc. closed 18.89% short of its 52-week high of $263.05, which the company reached on January 30th.